USA - NASDAQ:CRON - CA22717L1013 - Common Stock
Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 192 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.57% | ||
| ROE | 1.71% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 14.19% | ||
| GM | 32.74% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.64 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.65 | ||
| Quick Ratio | 23.53 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.4 | ||
| Fwd PE | 35.29 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.52
+0.04 (+1.61%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.4 | ||
| Fwd PE | 35.29 | ||
| P/S | 7.41 | ||
| P/FCF | N/A | ||
| P/OCF | 48.18 | ||
| P/B | 0.89 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.57% | ||
| ROE | 1.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 14.19% | ||
| GM | 32.74% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 224.14% | ||
| Cap/Sales | 22.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 24.65 | ||
| Quick Ratio | 23.53 | ||
| Altman-Z | 7.64 |
ChartMill assigns a fundamental rating of 5 / 10 to CRON.
ChartMill assigns a valuation rating of 1 / 10 to CRONOS GROUP INC (CRON). This can be considered as Overvalued.
CRONOS GROUP INC (CRON) has a profitability rating of 3 / 10.
The Earnings per Share (EPS) of CRONOS GROUP INC (CRON) is expected to decline by -115.3% in the next year.